Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Ozaki, T ^a   Wu, D ^a   Sugimoto, H ^a   Nagase, H ^a   Nakagawara, A ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

Apoptosis; DNA damage; HDAC6; P53; RUNX2

Indexed keywords

DNA; DOXORUBICIN; HISTONE DEACETYLASE 6; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR RUNX2; TUBACIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; NEGATIVE FEEDBACK; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DNA DAMAGE; DOWN-REGULATION; DOXORUBICIN; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84876924646     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.127     Document Type: Article

References (59)

1. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
2. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003; 10: 431-442.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
4. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262: 1980-1981.
5. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.
6. Velculescu VE, el-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996; 42: 858-868.
7. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
9. Pietenpol JA, Tokino T, Thiagalingam S, el-Deiry WS, Kinzler KW, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 1994; 91: 1998-2002.
10. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
11. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
12. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1132.
13. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126.
14. Sionov RV, Haupt Y. The cellular response to p53: The decision between life and death. Oncogene 1999; 18: 6145-6157.
15. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997; 15: 1001-1010.
16. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, Shioya H et al. Role for p300 in stabilization of p53 in the response to DNA damage. J Biol Chem 1999; 274: 1883-1886.
17. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 2001; 8: 781-794.
18. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006; 5: 395-405.
19. Lopez-Mateo I, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle 2012; 11: 3887-3895.
20. Yang Y, Wang C, Zhang P, Gao K, Wang D, Yu H et al. Polycomb group protein PHF1 regulates p53-dependent cell growth arrest and apoptosis. J Biol Chem 2012; 288: 529-539.
21. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279: 25549-25561.
22. Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM et al. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol 2010; 30: 3004-3015.
23. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-281.
24. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-387.
25. Anglin I, Passaniti A. Runx protein signaling in human cancers. Cancer Treat Res 2004; 119: 189-215.
26. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing Jr. AML1 the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
27. Takahashi A, Satake M, Yamaguchi-Iwai Y, Bae SC, Lu J, Maruyama M et al. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2. Blood 1995; 86: 607-616.
28. Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002; 111: 621-633.
29. Wu D, Ozaki T, Yoshihara Y, Kubo N, Nakagawara A. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 in response to DNA damage through complex formation and acetylation. J Biol Chem 2012; 288: 1353-1364.
30. Li QL, Ito K, Sakakura C, Fukamachi H, Ki Inoue, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124.
31. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology 2008; 75: 244-251.
32. Nicole Tsang YH, Wu XW, Lim JS,Wee Ong C, Salto-Tellez M, Ito K et al. Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer. Oncogene 2012; 32: 1488-1496.
33. He L, Zhao X, Wang H, Zhang P, Guo C, Huang C et al. RUNX3 mediates suppression of tumor growth and metastasis of human CCRCC by regulating cyclin related proteins and TIMP-1. PLoS One 2012; 7: e32961.
34. Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Ito Y et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 2010; 285: 16693-16703.
35. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764.
36. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89: 765-771.
37. Welch RD, Jones AL, Bucholz RW, Reinert CM, Tjia JS, Pierce WA et al. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998; 13: 1483-1490.
38. Lee MH, Kim YJ, Yoon WJ, Kim JI, Kim BG, Hwang YS et al. Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter. J Biol Chem 2005; 280: 35579-35587.
39. Karsenty G. The genetic transformation of bone biology. Genes Dev 1999; 13: 3037-3051.
40. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003; 56: 13-22.
41. Kayed H, Jiang X, Keleg S, Jesnowski R, Giese T, Berger MR et al. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer 2007; 97: 1106-1115.
42. Endo T, Ohta K, Kobayashi T. Expression and function of Cbf a-1/Runx2 in thyroid papillary carcinoma cells. J Clin Endocrinol Metab 2008; 93: 2409-2412.
43. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010; 101: 2670-2675.
44. Sase T, Suzuki T, Miura K, Shiiba K, Sato I, Nakamura Y et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer 2012; 131: 2284-2293.
45. van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem 2012; 287: 4503-4517.
46. Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M et al. Frequent amplification and rearrangement of chromosomal bands 6p1 2-p2 1 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004; 39: 11-21.
47. Browne G, Nesbitt H, Ming L, Stein GS, Lian JB, McKeown SR et al. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance. Br J Cancer 2012; 107: 1714-1721.
48. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 2006; 66: 2195-2201.
49. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002; 22: 7982-7992.
50. Namdar M, Perez G, Ngo L, Marks PA. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA 2010; 107: 20003-20008.
51. Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer 2010; 10: 202-211.
52. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010; 29: 811-821.
53. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005; 25: 8581-8591.
54. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 2000; 275: 651-656.
55. Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 2004; 279: 41998-42007.
56. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993; 72: 73-84.
57. Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000; 275: 15254-15264.
58. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 2008; 68: 7561-7569.
59. Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV et al. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012; 7: e44265.